The vascular smooth muscle cell: A therapeutic target in type 2 diabetes?

Clinical Science

Volumn 125, Issue 4, 2013, Pages 167-182

  Porter, Karen E ^a,b   Riches, Kirsten ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Metabolic memory; Novel therapeutics; Phenotype; Smooth muscle cell; Type 2 diabetes; Vascular complication

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYTOKINE; GLUCOSE; INSULIN; LIPID; MICRORNA;

ARTICLE; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CELL FUNCTION; CELL STRUCTURE; ENDOTHELIAL DYSFUNCTION; HOMEOSTASIS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; EPIGENESIS, GENETIC; HUMANS; HYPOGLYCEMIC AGENTS; MICRORNAS; MOLECULAR TARGETED THERAPY; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RISK;

EID: 84878104687     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120413     Document Type: Article

References (176)

1. Nilsson, P. M. (2008) Early vascular aging (EVA): consequences and prevention. Vasc. Health Risk Manag. 4, 547-552
2. Baker, R. G., Hayden, M. S. and Ghosh, S. (2011) NF-κB, inflammation, and metabolic disease. Cell Metab. 13, 11-22
3. Morley, J. E. (2008) Diabetes and aging: epidemiologic overview. Clin. Geriatr. Med. 24, 395-405
4. Kumar, P., and Clark, M. L. (2009) Clinical Medicine, Elsevier/Saunders, Edinburgh/New York
5. Booth, G. L., Kapral, M. K., Fung, K., and Tu, J. V. (2006) Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368, 29-36
6. Tarquini, R., Lazzeri, C., Pala, L., Rotella, C. M., and Gensini, G. F. (2011) The diabetic cardiomyopathy. Acta Diabetol. 48, 173-181
7. Brown, A., Reynolds, L. R., and Bruemmer, D. (2010) Intensive glycemic control and cardiovascular disease: an update. Nat. Rev. Cardiol. 7, 369-375
8. Flaherty, J. D., and Davidson, C. J. (2005) Diabetes and coronary revascularization. JAMA, J. Am. Med. Assoc. 293, 1501-1508
9. Scognamiglio, R., Negut, C., Ramondo, A., Tiengo, A., and Avogaro, A. (2006) Detection of coronary artery disease in asymptomatic patients with Type 2 diabetes mellitus. J. Am. Coll. Cardiol. 47, 65-71
10. Beckman, J. A., Creager, M. A., and Libby, P. (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, J. Am. Med. Assoc. 287, 2570-2581
11. Ruiter, M. S., van Golde, J. M., Schaper, N. C., Stehouwer, C. D., and Huijberts, M. S. (2010) Diabetes impairs arteriogenesis in the peripheral circulation: review of molecular mechanisms. Clin. Sci. 119, 225-238
12. Hakala, T., Pitkanen, O., Halonen, P., Mustonen, J., Turpeinen, A., and Hippelainen, M. (2005) Early and late outcome after coronary artery bypass surgery in diabetic patients. Scand. Cardiovasc. J. 39, 177-181
13. Kubal, C., Srinivasan, A. K., Grayson, A. D., Fabri, B. M., and Chalmers, J. A. (2005) Effect of risk-adjusted diabetes on mortality and morbidity after coronary artery bypass surgery. Ann. Thorac. Surg. 79, 1570-1576
14. Soldatos, G., Jandeleit-Dahm, K., Thomson, H., Formosa, M., D'orsa, K., Calkin, A. C., Cooper, M. E., Ahimastos, A. A., and Kingwell, B. A. (2011) Large artery biomechanics and diastolic dysfunctionin patients with Type 2 diabetes. Diabetic Med. 28, 54-60
15. Hess, K., and Grant, P. J. (2011) Inflammation and thrombosis in diabetes. Thromb. Haemostasis 105 (Suppl. 1), S43-S54
16. Corpus, R. A., George, P. B., House, J. A., Dixon, S. R., Ajluni, S. C., Devlin, W. H., Timmis, G. C., Balasubramaniam, M., and O'Neill, W. W. (2004) Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J. Am. Coll. Cardiol. 43, 8-14
17. Smith, Jr, S. C., Faxon, D., Cascio, W., Schaff, H., Gardner, T., Jacobs, A., Nissen, S., and Stouffer, R. (2002) Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients. Circulation 105, e165-e169
18. Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., and Sherwin, R. S. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J. Am. Coll. Cardiol. 53, 298-304
19. Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, Jr, D. C., Bigger, J. T., Buse, J. B., Cushman, W. C., Genuth, S., Ismail-Beigi, F., Grimm, Jr, R. H. et al. (2008) Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559
20. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., and Neil, H. A. (2008) 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359, 1577-1589
21. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D. et al. (2008) Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358, 2560-2572
22. Polak, J. F., Backlund, J. Y., Cleary, P. A., Harrington, A. P., O'Leary, D. H., Lachin, J. M., and Nathan, D. M. (2011) Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 60, 607-613
23. Pedersen, O., and Gaede, P. (2003) Intensified multifactorial intervention and cardiovascular outcome in Type 2 diabetes: the Steno-2 study. Metab. Clin. Exp. 52, 19-23
24. Reusch, J. E., and Wang, C. C. (2011) Cardiovascular disease in diabetes: where does glucose fit in? J. Clin. Endocrinol. Metab. 96, 2367-2376
25. Hermann, C., Assmus, B., Urbich, C., Zeiher, A. M., and Dimmeler, S. (2000) Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20, 402-409
26. Sydow, K., Mondon, C. E., and Cooke, J. P. (2005) Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc. Med. 10 (Suppl. 1), S35-S43
27. Bugiardini, R., Manfrini, O., Pizzi, C., Fontana, F., and Morgagni, G. (2004) Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 109, 2518-2523
28. Schachinger, V., Britten, M. B., and Zeiher, A. M. (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899-1906
29. Hadi, H. A., and Suwaidi, J. A. (2007) Endothelial dysfunction in diabetes mellitus. Vasc. Health Risk Manag. 3, 853-876
30. Rask-Madsen, C., and King, G. L. (2007) Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab. 3, 46-56
31. Zhang, H., Dellsperger, K. C., and Zhang, C. (2012) The link between metabolic abnormalities and endothelial dysfunction in Type 2 diabetes: an update. Basic Res. Cardiol. 107, 237
32. Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801
33. Owens, G. K. (1995) Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 75, 487-517
34. Gomez, D., and Owens, G. K. (2012) Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc. Res. 95, 156-164
35. Hao, H., Gabbiani, G., and Bochaton-Piallat, M. L. (2003) Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler. Thromb. Vasc. Biol. 23, 1510-1520
36. Ailawadi, G., Moehle, C. W., Pei, H., Walton, S. P., Yang, Z., Kron, I. L., Lau, C. L., and Owens, G. K. (2009) Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J. Thorac. Cardiovasc. Surg. 138, 1392-1399
37. Minamino, T., and Komuro, I. (2007) Vascular cell senescence: contribution to atherosclerosis. Circ. Res. 100, 15-26
38. Alexander, M. R., and Owens, G. K. (2012) Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu. Rev. Physiol. 74, 13-40
39. Han, M., Dong, L. H., Zheng, B., Shi, J. H., Wen, J. K., and Cheng, Y. (2009) Smooth muscle 22 α maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling. Life Sci. 84, 394-401
40. Etienne, P., Pares-Herbute, N., Mani-Ponset, L., Gabrion, J., Rabesandratana, H., Herbute, S., and Monnier, L. (1998) Phenotype modulation in primary cultures of aortic smooth muscle cells from streptozotocin-diabetic rats. Differentiation 63, 225-236
41. Thyberg, J., Nilsson, J., Palmberg, L., and Sjolund, M. (1985) Adult human arterial smooth muscle cells in primary culture. Modulation from contractile to synthetic phenotype. Cell Tissue Res. 239, 69-74
42. Thyberg, J., Blomgren, K., Hedin, U., and Dryjski, M. (1995) Phenotypic modulation of smooth muscle cells during the formation of neointimal thickenings in the rat carotid artery after balloon injury: an electron-microscopic and stereological study. Cell Tissue Res. 281, 421-433
43. Kawai-Kowase, K., and Owens, G. K. (2007) Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 292, C59-C69
44. Kawai-Kowase, K., Ohshima, T., Matsui, H., Tanaka, T., Shimizu, T., Iso, T., Arai, M., Owens, G. K., and Kurabayashi, M. (2009) PIAS1 mediates TGFβ-induced SM α-actin gene expression through inhibition of KLF4 function-expression by protein sumoylation. Arterioscler. Thromb. Vasc. Biol. 29, 99-106
45. Albinsson, S., Suarez, Y., Skoura, A., Offermanns, S., Miano, J. M., and Sessa, W. C. (2010) MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler. Thromb. Vasc. Biol. 30, 1118-1126
46. Cordes, K. R., and Srivastava, D. (2009) MicroRNA regulation of cardiovascular development. Circ. Res. 104, 724-732
47. Albinsson, S., and Sessa, W. C. (2011) Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury? Physiol. Genomics 43, 529-533
48. Cordes, K. R., Sheehy, N. T., White, M. P., Berry, E. C., Morton, S. U., Muth, A. N., Lee, T. H., Miano, J. M., Ivey, K. N., and Srivastava, D. (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460, 705-710
49. Huang, H., Xie, C., Sun, X., Ritchie, R. P., Zhang, J., and Chen, Y. E. (2010) miR-10a contributes to retinoid acid-induced smooth muscle cell differentiation. J. Biol. Chem. 285, 9383-9389
50. Xie, C., Huang, H., Sun, X., Guo, Y., Hamblin, M., Ritchie, R. P., Garcia-Barrio, M. T., Zhang, J., and Chen, Y. E. (2011) MicroRNA-1 regulates smooth muscle cell differentiation by repressing Kruppel-like factor 4. Stem Cells Dev. 20, 205-210
51. Ji, R., Cheng, Y., Yue, J., Yang, J., Liu, X., Chen, H., Dean, D. B., and Zhang, C. (2007) MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ. Res. 100, 1579-1588
52. Davis, B. N., Hilyard, A. C., Lagna, G., and Hata, A. (2008) SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454, 56-61
53. Kang, H., Davis-Dusenbery, B. N., Nguyen, P. H., Lal, A., Lieberman, J., Van, A. L., Lagna, G., and Hata, A. (2012) Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA-21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins. J. Biol. Chem. 287, 3976-3986
54. Wang, M., Li, W., Chang, G. Q., Ye, C. S., Ou, J. S., Li, X. X., Liu, Y., Cheang, T. Y., Huang, X. L., and Wang, S. M. (2011) MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler. Thromb. Vasc. Biol. 31, 2044-2053
55. Sarkar, J., Gou, D., Turaka, P., Viktorova, E., Ramchandran, R., and Raj, J. U. (2010) MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am. J. Physiol. Lung Cell Mol. Physiol. 299, L861-L871
56. Davis, B. N., Hilyard, A. C., Nguyen, P. H., Lagna, G., and Hata, A. (2009) Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J. Biol. Chem. 284, 3728-3738
57. Liu, X., Cheng, Y., Zhang, S., Lin, Y., Yang, J., and Zhang, C. (2009) A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ. Res. 104, 476-487
58. Chan, M. C., Hilyard, A. C., Wu, C., Davis, B. N., Hill, N. S., Lal, A., Lieberman, J., Lagna, G., and Hata, A. (2010) Molecular basis for antagonism between PDGF and the TGFβ family of signalling pathways by control of miR-24 expression. EMBO J. 29, 559-573
59. Cheng, Y., Liu, X., Yang, J., Lin, Y., Xu, D. Z., Lu, Q., Deitch, E. A., Huo, Y., Delphin, E. S., and Zhang, C. (2009) MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 105, 158-166
60. Small, E. M., and Olson, E. N. (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature 469, 336-342
61. Xin, M., Small, E. M., Sutherland, L. B., Qi, X., McAnally, J., Plato, C. F., Richardson, J. A., Bassel-Duby, R., and Olson, E. N. (2009) MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 23, 2166-2178
62. Torella, D., Iaconetti, C., Catalucci, D., Ellison, G. M., Leone, A., Waring, C. D., Bochicchio, A., Vicinanza, C., Aquila, I., Curcio, A. et al. (2011) MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ. Res. 109, 880-893
63. Wang, Y. S., Wang, H. Y., Liao, Y. C., Tsai, P. C., Chen, K. C., Cheng, H. Y., Lin, R. T., and Juo, S. H. (2012) MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc. Res. 95, 517-526
64. Forst, T., Hohberg, C., and Pfutzner, A. (2009) Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in Type 2 diabetic patients. Horm. Metab. Res. 41, 123-131
65. Faries, P. L., Rohan, D. I., Takahara, H., Wyers, M. C., Contreras, M. A., Quist, W. C., King, G. L., and Logerfo, F. W. (2001) Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration. J. Vasc. Surg. 33, 601-607
66. Madi, H. A., Riches, K., Warburton, P., O'Regan, D. J., Turner, N. A., and Porter, K. E. (2009) Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. Am. J. Physiol. Cell Physiol. 297, C1307-C1317
67. Kawano, M., Koshikawa, T., Kanzaki, T., Morisaki, N., Saito, Y., and Yoshida, S. (1993) Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: association with overexpression of PDGF β-receptors. Eur. J. Clin. Invest. 23, 84-90
68. Forbes, J. M., Yee, L. T., Thallas, V., Lassila, M., Candido, R., Jandeleit-Dahm, K. A., Thomas, M. C., Burns, W. C., Deemer, E. K., Thorpe, S. R. et al. (2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53, 1813-1823
69. Sawada, N., Itoh, H., Ueyama, K., Yamashita, J., Doi, K., Chun, T. H., Inoue, M., Masatsugu, K., Saito, T., Fukunaga, Y. et al. (2000) Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101, 2030-2033
70. Oikawa, S., Hayasaka, K., Hashizume, E., Kotake, H., Midorikawa, H., Sekikawa, A., Kikuchi, A., and Toyota, T. (1996) Human arterial smooth muscle cell proliferation in diabetes. Diabetes 45 (Suppl. 3), S114-S116
71. Chung, A. W., Luo, H., Tejerina, T., van, B. C., and Okon, E. B. (2007) Enhanced cell cycle entry and mitogen-activated protein kinase-signaling and downregulation of matrix metalloproteinase-1 and -3 in human diabetic arterial vasculature. Atherosclerosis 195, e1-e8
72. Turner, N. A., Ho, S., Warburton, P., O'Regan, D. J., and Porter, K. E. (2007) Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. J. Vasc. Surg. 45, 1022-1028
73. Henry, R. M., Kostense, P. J., Spijkerman, A. M., Dekker, J. M., Nijpels, G., Heine, R. J., Kamp, O., Westerhof, N., Bouter, L. M., and Stehouwer, C. D. (2003) Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 107, 2089-2095
74. Lorusso, R., Pentiricci, S., Raddino, R., Scarabelli, T. M., Zambelli, C., Villanacci, V., Burattin, A., Romanelli, G., Casari, S., Scelsi, R., and Giustina, A. (2003) Influence of Type 2 diabetes on functional and structural properties of coronary artery bypass conduits. Diabetes 52, 2814-2820
75. Klemm, A. H., Diez, G., Alonso, J. L., and Goldmann, W. H. (2009) Comparing the mechanical influence of vinculin, focal adhesion kinase and p53 in mouse embryonic fibroblasts. Biochem. Biophys. Res. Commun. 379, 799-801
76. Liu, A. C., and Gotlieb, A. I. (2007) Characterization of cell motility in single heart valve interstitial cells in vitro. Histol. Histopathol. 22, 873-882
77. El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G., Cooper, M. E., and Brownlee, M. (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205, 2409-2417
78. Yan, S. F., Ramasamy, R., and Schmidt, A. M. (2008) Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab. 4, 285-293
79. Sampson, M. J., and Hughes, D. A. (2006) Chromosomal telomere attrition as a mechanism for the increased risk of epithelial cancers and senescent phenotypes in Type 2 diabetes. Diabetologia 49, 1726-1731
80. Stout, R. W., Bierman, E. L., and Ross, R. (1975) Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ. Res. 36, 319-327
81. Pfeifle, B., and Ditschuneit, H. (1981) Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 20, 155-158
82. Pfeifle, B., Hamann, H., Fussganger, R., and Ditschuneit, H. (1987) Insulin as a growth regulator of arterial smooth muscle cells: effect of insulin of I. G.F.I. Diabete Metab. 13, 326-330
83. Bornfeldt, K. E., Raines, E. W., Nakano, T., Graves, L. M., Krebs, E. G., and Ross, R. (1994) Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J. Clin. Invest. 93, 1266-1274
84. Ruiz-Torres, A., Lozano, R., Melon, J., and Carraro, R. (2005) On how insulin may influence ageing and become atherogenic throughout the insulin-like growth factor-1 receptor pathway: in vitro studies with human vascular smooth muscle cells. Gerontology 51, 225-230
85. Mughal, R. S., Scragg, J. L., Lister, P., Warburton, P., Riches, K., O'Regan, D. J., Ball, S. G., Turner, N. A., and Porter, K. E. (2010) Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia 53, 1761-1771
86. Kapur, A., Hall, R. J., Malik, I. S., Qureshi, A. C., Butts, J., de Belder, M., Baumbach, A., Angelini, G., de Belder, A., Oldroyd, K. G. et al. (2010) Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J. Am. Coll. Cardiol. 55, 432-440
87. Kornowski, R., Mintz, G. S., Kent, K. M., Pichard, A. D., Satler, L. F., Bucher, T. A., Hong, M. K., Popma, J. J., and Leon, M. B. (1997) Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 95, 1366-1369
88. Wang, C. C., Gurevich, I., and Draznin, B. (2003) Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 52, 2562-2569
89. Avena, R., Mitchell, M. E., Neville, R. F., and Sidawy, A. N. (1998) The additive effects of glucose and insulin on the proliferation of infragenicular vascular smooth muscle cells. J. Vasc. Surg. 28, 1033-1038
90. Cifarelli, V., Luppi, P., Tse, H. M., He, J., Piganelli, J., and Trucco, M. (2008) Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-κB activation in vascular smooth muscle cells. Atherosclerosis 201, 248-257
91. Kobayashi, Y., Naruse, K., Hamada, Y., Nakashima, E., Kato, K., Akiyama, N., Kamiya, H., Watarai, A., Nakae, M., Oiso, Y., and Nakamura, J. (2005) Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia 48, 2396-2401
92. Nakamura, J., Kasuya, Y., Hamada, Y., Nakashima, E., Naruse, K., Yasuda, Y., Kato, K., and Hotta, N. (2001) Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia 44, 480-487
93. Yamamoto, M., Acevedo-Duncan, M., Chalfant, C. E., Patel, N. A., Watson, J. E., and Cooper, D. R. (2000) Acute glucose-induced downregulation of PKC-βII accelerates cultured VSMC proliferation. Am. J. Physiol. Cell Physiol. 279, C587-C595
94. Suzuki, L. A., Poot, M., Gerrity, R. G., and Bornfeldt, K. E. (2001) Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes 50, 851-860
95. Sacco, M., Pellegrini, F., Roncaglioni, M. C., Avanzini, F., Tognoni, G., and Nicolucci, A. (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in Type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26, 3264-3272
96. Russo, I., Viretto, M., Barale, C., Mattiello, L., Doronzo, G., Pagliarino, A., Cavalot, F., Trovati, M., and Anfossi, G. (2012) High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes 61, 2913-2921
97. Ajjan, R., Storey, R. F., and Grant, P. J. (2008) Aspirin resistance and diabetes mellitus. Diabetologia 51, 385-390
98. Hegab, Z., Gibbons, S., Neyses, L., and Mamas, M. A. (2012) Role of advanced glycation end products in cardiovascular disease. World J. Cardiol. 4, 90-102
99. Park, S., Yoon, S. J., Tae, H. J., and Shim, C. Y. (2011) RAGE and cardiovascular disease. Front. Biosci. 16, 486-497
100. Reddy, M. A., Li, S. L., Sahar, S., Kim, Y. S., Xu, Z. G., Lanting, L., and Natarajan, R. (2006) Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J. Biol. Chem. 281, 13685-13693
101. Cai, Q., Li, B. Y., Gao, H. Q., Zhang, J. H., Wang, J. F., Yu, F., Yin, M., and Zhang, Z. (2011) Grape seed procyanidin b2 inhibits human aortic smooth muscle cell proliferation and migration induced by advanced glycation end products. Biosci. Biotechnol. Biochem. 75, 1692-1697
102. Zhou, Z., Wang, K., Penn, M. S., Marso, S. P., Lauer, M. A., Forudi, F., Zhou, X., Qu, W., Lu, Y., Stern, D. M. et al. (2003) Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107, 2238-2243
103. Grozinger, G., Schmehl, J., Bantleon, R., Kehlbach, R., Mehra, T., Claussen, C., and Wiesinger, B. (2012) Decreased neointimal extracellular matrix formation in RAGE-knockout mice after microvascular denudation. Cardiovasc. Intervent. Radiol. 35, 1439-1447
104. Chen, K. C., Hsieh, I. C., Hsi, E., Wang, Y. S., Dai, C. Y., Chou, W. W., and Juo, S. H. (2011) Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1. J. Cell Sci. 124, 4115-4124
105. Zhu, G., Chen, H., and Zhang, W. (2011) Phenotype switch of vascular smooth muscle cells after siRNA silencing of filamin. Cell Biochem. Biophys. 61, 47-52
106. Chen, K. C., Wang, Y. S., Hu, C. Y., Chang, W. C., Liao, Y. C., Dai, C. Y., and Juo, S. H. (2011) OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J. 25, 1718-1728
107. Ma, S., Yang, D., Li, D., Tang, B., and Yang, Y. (2011) Oleic acid induces smooth muscle foam cell formation and enhances atherosclerotic lesion development via CD36. Lipids Health Dis. 10, 53
108. Rong, J. X., Shapiro, M., Trogan, E., and Fisher, E. A. (2003) Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc. Natl. Acad. Sci. U.S.A. 100, 13531-13536
109. Artwohl, M., Lindenmair, A., Roden, M., Waldhausl, W. K., Freudenthaler, A., Klosner, G., Ilhan, A., Luger, A., and Baumgartner-Parzer, S. M. (2009) Fatty acids induce apoptosis in human smooth muscle cells depending on chain length, saturation, and duration of exposure. Atherosclerosis 202, 351-362
110. Chung, J. H., Jeon, H. J., Hong, S. Y., Lee, D. L., Lee, K. H., Kim, S. H., Han, Y. S., Manabe, I., Miller, Y. I., and Lee, S. H. (2012) Palmitate promotes the paracrine effects of macrophages on vascular smooth muscle cells: the role of bone morphogenetic proteins. PLoS ONE 7, e29100
111. Lamers, D., Schlich, R., Greulich, S., Sasson, S., Sell, H., and Eckel, J. (2011) Oleic acid and adipokines synergize in inducing proliferation and inflammatory signalling in human vascular smooth muscle cells. J. Cell Mol. Med. 15, 1177-1188
112. Liao, P. L., Cheng, Y. W., Li, C. H., Wang, Y. T., and Kang, J. J. (2010) 7-Ketocholesterol and cholesterol-5α,6α-epoxide induce smooth muscle cell migration and proliferation through the epidermal growth factor receptor/phosphoinositide 3-kinase/Akt signaling pathways. Toxicol. Lett. 197, 88-96
113. Dandona, P., Aljada, A., and Bandyopadhyay, A. (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25, 4-7
114. Barillari, G., Albonici, L, Incerpi, S., Bogetto, L, Pistritto, G., Volpi, A., Ensoli, B., and Manzari, V. (2001) Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing a5/31 integrin expression and function. Atherosclerosis 154, 377-385
115. Viedt, C, Vogel, J., Athanasiou, T., Shen, W., Orth, S. R., Kubler, W., and Kreuzer, J. (2002) Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-KB and activator protein-1. Arterioscler. Thromb. Vasc. Biol. 22, 914-920
116. Reddy, M. A., and Natarajan, R. (2011) Epigenetic mechanisms in diabetic vascular complications. Cardiovasc. Res. 90, 421-429
117. Villeneuve, L. M., Reddy, M. A., Lanting, L. L, Wang, M., Meng, L., and Natarajan, R. (2008) Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl. Acad. Sci. U.S.A. 105, 9047-9052
118. Srinivasan, K., and Ramarao, P. (2007) Animal models in Type 2 diabetes research: an overview. Indian J. Med. Res. 125, 451-472
119. Schreyer, S. A., Wilson, D. L., and LeBoeuf, R. C. (1998) C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis 136, 17-24
120. Boquist, L, Hellman, B., Lernmark, A., and Taljedal, I. B. (1974) Influence of the mutation "diabetes" on insulin release and islet morphology in mice of different genetic backgrounds. J. Cell Biol. 62, 77-89
121. Navedo, M. F., Takeda, Y, Nieves-Cintron, M., Molkentin, J. D., and Santana, L. F. (2010) Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle cells. Am. J. Physiol. Cell Physiol. 298, C211-C220
122. Velmurugan, G. V., and White, C. (2012) Calcium homeostasis in vascular smooth muscle cells is altered in Type 2 diabetes by Bcl-2 protein modulation of InsP3R calcium release channels. Am. J. Physiol. Heart Circ. Physiol. 302, H124-H134
123. Su, W., Xie, Z., Guo, Z., Duncan, M. J., Lutshumba, J., and Gong, M. C. (2012) Altered clock gene expression and vascular smooth muscle diurnal contractile variations in Type 2 diabetic db/db mice. Am. J. Physiol. Heart Circ. Physiol. 302, H621-H633
124. Guo, Z., Su, W., Allen, S., Pang, H., Daugherty, A., Smart, E., and Gong, M. C. (2005) COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc. Res. 67, 723-735
125. Salzberg, S. P, Filsoufi, F., Anyanwu, A., von Harbou, K., Karlof, E., Carpentier, A., Dansky, H. M., and Adams, D. H. (2006) Increased neointimal formation after surgical vein grafting in a murine model of Type 2 diabetes. Circulation 114, I302-I307
126. Li, S. L, Reddy, M. A., Cai, Q., Meng, L, Yuan, H., Lanting, L., and Natarajan, R. (2006) Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes 55, 2611-2619
127. Freidja, M. L., Tarhouni, K., Toutain, B., Fassot, C, Loufrani, L., and Henrion, D. (2012) The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of Type 2 diabetes. Diabetes 61, 1562-1572
128. Ahanchi, S. S., Varu, V. N., Tsihlis, N. D., Martinez, J., Pearce, C. G., Kapadia, M. R., Jiang, Q., Saavedra, J. E., Keefer, L. K., Hrabie, J. A., and Kibbe, M. R. (2008) Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 295, H2388-H2398
129. Jacob, A., Smolenski, A., Lohmann, S. M., and Begum, N. (2004) MKP-1 expression and stabilization and cGK Ia prevent diabetes- associated abnormalities in VSMC migration. Am. J. Physiol. Cell Physiol. 287, C1077-C1086
130. Ragolia, L., Palaia, T., Koutrouby, T. B., and Maesaka, J. K. (2004) Inhibition of cell cycle progression and migration of vascular smooth muscle cells by prostaglandin D2 synthase: resistance in diabetic Goto-Kakizaki rats. Am. J. Physiol. Cell Physiol. 287, C1273-C1281
131. Wakabayashi, I., Nakano, T., and Takahashi, Y. (2010) Enhancement of interleukin-1β-induced iNOS expression in cultured vascular smooth muscle cells of Goto-Kakizaki diabetes rats. Eur. J. Pharmacol. 629, 1-6
132. Sandu, O. A., Ragolia, L., and Begum, N. (2000) Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes 49, 2178-2189
133. Neeb, Z. P., Edwards, J. M., Alloosh, M., Long, X., Mokelke, E. A., and Sturek, M. (2010) Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine. Comp Med. 60, 300-315
134. Xi, S., Yin, W., Wang, Z., Kusunoki, M., Lian, X., Koike, T., Fan, J., and Zhang, Q. (2004) A minipig model of high-fat/ high-sucrose diet-induced diabetes and atherosclerosis. Int. J. Exp. Pathol. 85, 223-231
135. Cooper, M. E. (2009) Metabolic memory: implications for diabetic vascular complications. Pediatr. Diabetes 10, 343-346
136. Aizawa, T., and Funase, Y. (2011) Intervention at the very early stage of Type 2 diabetes. Diabetologia 54, 703-704
137. Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., and El-Osta, A. (2009) Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58, 1229-1236
138. Davignon, J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43
139. Kiyan, J., Kusch, A., Tkachuk, S., Kramer, J., Haller, H., Dietz, R., Smith, G., and Dumler, I. (2007) Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor. Atherosclerosis 195, 254-261
140. Margaritis, M., Channon, K. M., and Antoniades, C. (2012) Statins and vein graft failure in coronary bypass surgery. Curr. Opin. Pharmacol. 12, 172-180
141. Simsek, S., Schalkwijk, C. G., and Wolffenbuttel, B. H. (2012) Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes - the CORALL study. Diabetic Med. 29, 628-631
142. Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, Jr, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G. et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207
143. Cao, Z., and Cooper, M. E. (2012) Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with Type 2 diabetes. Acta Diabetol. 49, 243-254
144. Halterman, J. A., Kwon, H. M., Zargham, R., Bortz, P. D., and Wamhoff, B. R. (2011) Nuclear factor of activated T cells 5 regulates vascular smooth muscle cell phenotypic modulation. Arterioscler. Thromb. Vasc. Biol. 31, 2287-2296
145. Kohler, R., Wulff, H., Eichler, I., Kneifel, M., Neumann, D., Knorr, A., Grgic, I., Kampfe, D., Si, H., Wibawa, J. et al. (2003) Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 108, 1119-1125
146. Tharp, D. L., Wamhoff, B. R., Wulff, H., Raman, G., Cheong, A., and Bowles, D. K. (2008) Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler. Thromb. Vasc. Biol. 28, 1084-1089
147. Su, X. L., Wang, Y., Zhang, W., Zhao, L. M., Li, G. R., and Deng, X. L. (2011) Insulin-mediated upregulation of KCa3.1 channels promotes cell migration and proliferation in rat vascular smooth muscle. J. Mol. Cell Cardiol. 51, 51-57
148. Nazari-Jahantigh, M., Wei, Y., and Schober, A. (2012) The role of microRNAs in arterial remodelling. Thromb. Haemostasis 107, 611-618
149. Gillies, C. L., Abrams, K. R., Lambert, P. C., Cooper, N. J., Sutton, A. J., Hsu, R. T., and Khunti, K. (2007) Pharmacological and lifestyle interventions to prevent or delay Type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334, 299
150. Ceriello, A., Ihnat, M. A., and Thorpe, J. E. (2009) The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J. Clin. Endocrinol. Metab. 94, 410-415
151. Herder, C., Karakas, M., and Koenig, W. (2011) Biomarkers for the prediction of Type 2 diabetes and cardiovascular disease. Clin. Pharmacol. Ther. 90, 52-66
152. Koenig, W., and Khuseyinova, N. (2007) Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler. Thromb. Vasc. Biol. 27, 15-26
153. Jankun, J., Al-Senaidy, A., and Skrzypczak-Jankun, E. (2012) Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? Int. J. Mol. Med. 29, 3-11
154. Kampoli, A. M., Tousoulis, D., Briasoulis, A., Latsios, G., Papageorgiou, N., and Stefanadis, C. (2011) Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by Type 2 diabetes mellitus. Curr. Pharm. Des. 17, 4147-4158
155. Noto, H., Chitkara, P., and Raskin, P. (2006) The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes. J. Diabetes Complications 20, 343-348
156. Jamaluddin, M. S., Weakley, S. M., Zhang, L., Kougias, P., Lin, P. H., Yao, Q., and Chen, C. (2011) miRNAs: roles and clinical applications in vascular disease. Expert Rev. Mol. Diagn. 11, 79-89
157. Ferland-McCollough, D., Ozanne, S. E., Siddle, K., Willis, A. E., and Bushell, M. (2010) The involvement of microRNAs in Type 2 diabetes. Biochem. Soc. Trans. 38, 1565-1570
158. Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., Mayr, A., Weger, S., Oberhollenzer, F., Bonora, E. et al. (2010) Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in Type 2 diabetes. Circ. Res. 107, 810-817
159. Kong, L., Zhu, J., Han, W., Jiang, X., Xu, M., Zhao, Y., Dong, Q., Pang, Z., Guan, Q., Gao, L. et al. (2011) Significance of serum microRNAs in pre-diabetes and newly diagnosed Type 2 diabetes: a clinical study. Acta Diabetol. 48, 61-69
160. Pandey, A. K., Agarwal, P., Kaur, K., and Datta, M. (2009) MicroRNAs in diabetes: tiny players in big disease. Cell. Physiol. Biochem. 23, 221-232
161. Villeneuve, L. M., Kato, M., Reddy, M. A., Wang, M., Lanting, L., and Natarajan, R. (2010) Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 59, 2904-2915
162. Jordan, S. D., Kruger, M., Willmes, D. M., Redemann, N., Wunderlich, F. T., Bronneke, H. S., Merkwirth, C., Kashkar, H., Olkkonen, V. M., Bottger, T. et al. (2011) Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated Akt activation and impairs glucose metabolism. Nat. Cell Biol. 13, 434-446
163. Dey, N., Das, F., Mariappan, M. M., Mandal, C. C., Ghosh-Choudhury, N., Kasinath, B. S., and Choudhury, G. G. (2011) MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J. Biol. Chem. 286, 25586-25603
164. Zhang, Z., Peng, H., Chen, J., Chen, X., Han, F., Xu, X., He, X., and Yan, N. (2009) MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 583, 2009-2014
165. Reddy, M. A., Jin, W., Villeneuve, L., Wang, M., Lanting, L., Todorov, I., Kato, M., and Natarajan, R. (2012) Pro-inflammatory role of MicroRNA-200 in vascular smooth muscle cells from diabetic mice. Arterioscler. Thromb. Vasc. Biol. 32, 721-729
166. Montgomery, R. L., and van Rooij, E. (2011) Therapeutic advances in microRNA targeting. J. Cardiovasc. Pharmacol. 57, 1-7
167. Nana-Sinkam, S. P., and Croce, C. M. (2011) MicroRNAs as therapeutic targets in cancer. Transl. Res. 157, 216-225
168. Spin, J. M., Maegdefessel, L., and Tsao, P. S. (2012) Vascular smooth muscle cell phenotypic plasticity: focus on chromatin remodelling. Cardiovasc. Res. 95, 147-155
169. Lorenzen, J. M., Martino, F., and Thum, T. (2012) Epigenetic modifications in cardiovascular disease. Basic Res. Cardiol. 107, 245
170. Udali, S., Guarini, P., Moruzzi, S., Choi, S. W., and Friso, S. (2013) Cardiovascular epigenetics: from DNA methylation to microRNAs. Mol. Aspects Med., doi: 10.1016/j.mam.2012. 08.001
171. Villeneuve, L. M., Reddy, M. A., and Natarajan, R. (2011) Epigenetics: deciphering its role in diabetes and its chronic complications. Clin. Exp. Pharmacol. Physiol. 38, 451-459
172. Pirola, L., Balcerczyk, A., Okabe, J., and El-Osta, A. (2010) Epigenetic phenomena linked to diabetic complications. Nat. Rev. Endocrinol. 6, 665-675
173. Maier, S., and Olek, A. (2002) Diabetes: a candidate disease for efficient DNA methylation profiling. J. Nutr. 132, 2440S-2443S
174. Pirola, L., Balcerczyk, A., Tothill, R. W., Haviv, I., Kaspi, A., Lunke, S., Ziemann, M., Karagiannis, T., Tonna, S., Kowalczyk, A. et al. (2011) Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Res. 21, 1601-1615
175. American Association for Cancer Research Human Epigenome Task Force; European Union, Network of Excellence, Scientific Advisory Board (2008) Moving AHEAD with an international human epigenome project. Nature 454, 711-715
176. Villeneuve, L. M., and Natarajan, R. (2010) The role of epigenetics in the pathology of diabetic complications. Am. J. Physiol. Renal Physiol. 299, F14-F25